Clarus Therapeutics (OTCMKTS:CRXTQ) and Biomerica (NASDAQ:BMRA) Head-To-Head Review

Biomerica (NASDAQ:BMRA) and Clarus Therapeutics (OTCMKTS:CRXTQ) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability and analyst recommendations.

Profitability

This table compares Biomerica and Clarus Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Biomerica	-96.49%	-98.14%	-70.42%
Clarus Therapeutics	N/A	N/A	N/A

Analyst Ratings

This is a summary of recent ratings and recommmendations for Biomerica and Clarus Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biomerica	1	0	0	0	1.00
Clarus Therapeutics	0	0	0	0	0.00

Biomerica currently has a consensus target price of $9.00, indicating a potential upside of 330.62%. Given Biomerica’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Biomerica is more favorable than Clarus Therapeutics.

Institutional & Insider Ownership

22.3% of Biomerica shares are owned by institutional investors. 18.0% of Biomerica shares are owned by company insiders. Comparatively, 5.3% of Clarus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Biomerica and Clarus Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biomerica	$5.31 million	1.22	-$4.97 million	($0.89)	-2.35
Clarus Therapeutics	N/A	N/A	N/A	N/A	N/A

Clarus Therapeutics has lower revenue, but higher earnings than Biomerica.

Summary

Biomerica beats Clarus Therapeutics on 5 of the 8 factors compared between the two stocks.

About Biomerica

Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops products to indicate if a person has been infected by COVID-19. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.

About Clarus Therapeutics

Clarus Therapeutics Holdings, Inc., a pharmaceutical company, focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen therapies for inflammatory breast disease and certain forms of breast cancer; and license agreement with The Royal Institution for the Advancement of Learning/McGill University to develop and commercialize McGill's proprietary technology designed to treat conditions associated with CoQ10 deficiencies in humans. Clarus Therapeutics Holdings, Inc. was founded in 2003 and is based in Northbrook, Illinois.